Innovative AAV Production Process Funded by NIIMBL Grant: ChromaTan and Landmark Bio Collaborate
ChromaTan Inc. and Landmark Bio PBLLC have recently secured a grant from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to enhance the production process of intensified recombinant adeno-associated virus (AAV). This collaborative effort aims to develop a cost-effective, scalable manufacturing platform for AAV-based gene therapy vectors, signaling a significant advancement in biopharmaceutical manufacturing.
The collaboration brings together ChromaTan's BioRMB™ technology and Kascade instrumentation with Landmark Bio's extensive knowledge in viral vector development, manufacturing processes, and quality controls. By focusing on purification efficiency and process intensification, this partnership seeks to stem into multiple AAV serotypes, ultimately refining the manufacturing journey of gene therapies.
Oleg Shinkazh, CEO of ChromaTan, expressed excitement regarding the partnership, emphasizing how the grant will facilitate the evolution of their advanced manufacturing technology. He highlighted the significance of sharing findings not only with their partner but also with the wider NIIMBL community, promoting collective growth and innovation.
With the expectation of reducing resin costs and improving recovery rates, this technology has the promising potential to boost production capacity while simultaneously lowering the overall cost of goods. Dr. Gregg Nyberg, CTO of Landmark Bio, shared the anticipation of integrating continuous chromatography into their Postmark™ AAV manufacturing platform, highlighting how this synergy will enhance the accessibility of groundbreaking treatments for patients in need.
Sandeep Kedia, a senior technology fellow at NIIMBL, spoke on NIIMBL's mission to advance high-potential technologies through collaborative efforts, expressing optimism about the impact this project will have on AAV vector production within the biopharmaceutical landscape.
NIIMBL operates as a public-private partnership dedicated to speeding up biopharmaceutical innovation and enhancing manufacturing standards. Supported by significant funding from the U.S. Department of Commerce and collaboration with various industry leaders, NIIMBL is committed to fostering a robust biopharmaceutical manufacturing workforce in the United States.
ChromaTan, Inc. is based in Spring House, PA, specializing in biomanufacturing processes through its proprietary BioRMB™ technology, which allows continuous purification of biologic feeds. The technology is applicable to viral vectors, mRNA, recombinant proteins, and more. For more information, visit ChromaTan.
Landmark Bio aims to accelerate drug development through collaboration, overcoming challenges in manufacturing through partnerships among key players in academia and the life sciences sector. Their collaboration with prestigious institutions like Harvard and MIT underlines their commitment to innovation in the healthcare industry. More details are available at Landmark Bio.
This collaboration between ChromaTan and Landmark Bio, backed by NIIMBL funding, marks a notable turning point in the production of AAV-based gene therapies. The implications of this project extend beyond mere manufacturing, embodying a commitment to making advanced treatments more accessible to patients worldwide. As the project progresses, it is anticipated to not only push the boundaries of AAV technology but also strengthen the foundational capabilities for future biopharmaceutical advances.
Collaborative Endeavor
The collaboration brings together ChromaTan's BioRMB™ technology and Kascade instrumentation with Landmark Bio's extensive knowledge in viral vector development, manufacturing processes, and quality controls. By focusing on purification efficiency and process intensification, this partnership seeks to stem into multiple AAV serotypes, ultimately refining the manufacturing journey of gene therapies.
Oleg Shinkazh, CEO of ChromaTan, expressed excitement regarding the partnership, emphasizing how the grant will facilitate the evolution of their advanced manufacturing technology. He highlighted the significance of sharing findings not only with their partner but also with the wider NIIMBL community, promoting collective growth and innovation.
Potential Impact of the Technology
With the expectation of reducing resin costs and improving recovery rates, this technology has the promising potential to boost production capacity while simultaneously lowering the overall cost of goods. Dr. Gregg Nyberg, CTO of Landmark Bio, shared the anticipation of integrating continuous chromatography into their Postmark™ AAV manufacturing platform, highlighting how this synergy will enhance the accessibility of groundbreaking treatments for patients in need.
Sandeep Kedia, a senior technology fellow at NIIMBL, spoke on NIIMBL's mission to advance high-potential technologies through collaborative efforts, expressing optimism about the impact this project will have on AAV vector production within the biopharmaceutical landscape.
About NIIMBL and Support Structure
NIIMBL operates as a public-private partnership dedicated to speeding up biopharmaceutical innovation and enhancing manufacturing standards. Supported by significant funding from the U.S. Department of Commerce and collaboration with various industry leaders, NIIMBL is committed to fostering a robust biopharmaceutical manufacturing workforce in the United States.
Company Profiles
ChromaTan, Inc. is based in Spring House, PA, specializing in biomanufacturing processes through its proprietary BioRMB™ technology, which allows continuous purification of biologic feeds. The technology is applicable to viral vectors, mRNA, recombinant proteins, and more. For more information, visit ChromaTan.
Landmark Bio aims to accelerate drug development through collaboration, overcoming challenges in manufacturing through partnerships among key players in academia and the life sciences sector. Their collaboration with prestigious institutions like Harvard and MIT underlines their commitment to innovation in the healthcare industry. More details are available at Landmark Bio.
Conclusion
This collaboration between ChromaTan and Landmark Bio, backed by NIIMBL funding, marks a notable turning point in the production of AAV-based gene therapies. The implications of this project extend beyond mere manufacturing, embodying a commitment to making advanced treatments more accessible to patients worldwide. As the project progresses, it is anticipated to not only push the boundaries of AAV technology but also strengthen the foundational capabilities for future biopharmaceutical advances.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.